Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Autor: M Datoo, Thomas A. Rawlinson, C Brown-O’Sullivan, Hodgson Shc., C White, B Oguti, Eleanor Berrie, N Moya, S Felle, H Sanders, Adam J. Ritchie, M M Hou, J Drake, E Brunt, D Rajapaksa, S Provstgaard-Morys, G Gorini, Elizabeth Nuthall, J Burbage, C Munro, L Bates, J A Tree, E Y Jones, R Makinson, O E Muhanna, N Borthwick, Andreas C. Themistocleous, I Rudiansyah, Emary Krw., A Batten, D Jenkin, D J Smith, I Vichos, N Douglas, Susanna Dunachie, Hazel Morrison, S Marinou, P Osborne, A Szigeti, Bassam Hallis, Alexander J. Mentzer, Christina Dold, T Brenner, K Parker, E H Arbe-Barnes, G Meddaugh, S Lipworth, J Towner, N Turner, E Hamilton, C Downing, L Gracie, C J Cunningham, P Matthews, H Humphries, Y Peng, N Tran, I Satti, N Byard, Shuo Feng, Ciaran Gilbride, R E Drury, K Radia, D Bellamy, R Tarrant, E Howe, Daniel J. Phillips, L Cifuentes, X L Yao, Elizabeth R. Allen, L Allen, B Hanumunthadu, K Godwin, E Francis, K Sanders, H Parracho, R Kailath, N Baker, J McGlashan, S Rhead, F Jackson, S Tonks, A Ali, S Murphy, Larwood Jpj., L Tinh, T Wrin, A Linder, Irina Chelysheva, Catherine M. Green, Elizabeth J. Kelly, C Datta, B Khozoee, H Roberts, Miles W. Carroll, P M Folegatti, C V Arancibia-Cárcamo, Julian C. Knight, E Marlow, P C Proud, A Truby, Crocker Wem., Hannah Robinson, J Keen, E J Penn, L Loew, Elizabeth A. Clutterbuck, D Zizi, N Owino, E Boland, J McEwan, N G Marchevsky, E Morey, Brian Angus, M P Peralta Alvarez, P Mweu, A Killen, E A Lees, Amy Boyd, Watson Mee., A Tomic, M E Wand, T B King, S Jauregui, C W Larkworthy, S Salvador, I J Taylor, D Pulido, Fay L. Nugent, M Patrick-Smith, A T Worth, Merryn Voysey, S A Harris, T M Thomas, A Shea, Teresa Lambe, L Blackwell, R Halkerston, Katie J. Ewer, D O’Connor, L Kingham-Page, P Brown, R Fisher, S J Morris, B Huang, Michelle Fuskova, D O’Donnell, A Lelliott, E R Pabon, J Kinch, M Thomas, H Garlant, M N Ramasamy, Daniel B. Wright, K Mansatta, K Taylor, F Cappuccini, D Kerr, Jordan R. Barrett, E Schofield, Yrene Themistocleous, R Varughese, A Beveridge, M R English, D Pipini, Sandra Belij-Rammerstorfer, S Camara, F Ramos Lopez, N Howell, J Frater, J Aboagye, X Liu, A Noé, L Silva-Reyes, Huw Davies, F R Donnellan, Alison M. Lawrie, Andrew J. Pollard, E Bolam, C Sedik, Hill Avs., Simon Kerridge, R te Water Naude, Alexandra J. Spencer, C Petropoulos, Maria Moore, K Jeffery, C Oliveria, K Pfafferott, G Gupta, Catherine C. Smith, A M Lias, G Morshead, D DiTirro, N Mirtorabi, H Ratcliffe, M J Elmore, R Lopez Ramon, S Jackson, K Jones, Y Li, Stephen Taylor, M Madhavan, I Shaik, Yama F Mujadidi, J Alderson, I Baleanu, Matthew D. Snape, M Bittaye, P J O’Reilly, R White, K O’Brien, Breeze E. Cavell, J Muller, Kelly M. Thomas, M Cao, S Field, S Roche, R Tanner, D M Kelly, R Anslow, L King, Annina B. Schmid, P Iveson, Ian D. Poulton, R Song, C L Blundell, R Beckley, T Demissie, Jack Mellors, K J Ford, Sarah E. Silk, J Furze, D Harrison, K R Buttigieg, Amy Flaxman, J Chadwick, J A Henry, R Morgans, L McInroy, G Screaton, V Olchawski, S Liu, L Khan, R Morter, P Galian-Rubio, T C Hart, G Hodges, Abdessamad Tahiri-Alaoui, J Perring, S Hawkins, Emma Plested, S Koleva, B E Damratoski, L Walker, Lisa Stockdale, P Baker, G Mallett, Angela M. Minassian, E Stafford, M K Verheul, M Carr, D Knott, Nick J. Edwards, J Fowler, Sarah C. Gilbert, A Thompson, Hannah Sharpe, Andrew Gorringe, Marta Ulaszewska, Christine S. Rollier, C P Conlon, R Colin-Jones, C Turner, Eleanor Barnes, E Mukhopadhyay, S Bibi, E M Bijker, R Cooper, D T Skelly, N S Coombes, J L Marshall, Tao Dong, Jennifer Hill, C Di Maso, K Beadon, Alexander D. Douglas, Cho J-S., Sean C. Elias, Parvinder K. Aley, S Leung, Paul Klenerman, I Cabrera Puig, K R Bewley, E Clark, S Kelly, P Williams, J Hamlyn, Megan Baker, C F Da Silva, R Drake-Brockman

Publikováno v: Nature Medicine. 27:1113-1113

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22b817d0db14346f513b67f40ab92038
https://doi.org/10.1038/s41591-021-01372-z

Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes

Autor: Evy Vandemeulebroucke, Peppy Rebello, Ibrahim Al Bakir, William J. Jusko, E Bolam, Paweł Wiczling, Annette-G Ziegler, Chantal Mathieu, Bart Keymeulen, Geoff Hale, Lucienne Chatenoud, Herman Waldmann

Publikováno v: Journal of clinical pharmacology. 50(11)

Otelixizumab is a chimeric CD3 antibody that has been genetically engineered to remove the glycosylation site in the Fc domain. This limits its ability to bind to complement or Fc receptors and reduces the risk of adverse clinical reactions due to cy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f167e311334bb702ea4be6ba8d6077
http://ora.ox.ac.uk/objects/uuid:5f03757f-a5b6-4ae2-a737-180e856004c3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.